Estimated GFR in autosomal dominant polycystic kidney disease: errors of an unpredictable method

BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) causes about 10% of cases of end stage renal disease. Disease progression rate is heterogeneous. Tolvaptan is presently the only specific therapeutic option to slow kidney function decline in adults at risk of rapidly progressing ADPKD...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodríguez, Rosa Miquel, Luis-Lima, Sergio, Fernandez, Juan Manuel, Gómez, María Vanesa Pérez, Toledo, Beatriz González, Cobo, Marian, Delgado-Mallén, Patricia, Escamilla, Beatriz, Marco, Cristina Oramas, Estupiñán, Sara, Perera, Coriolano Cruz, Mena, Natalia Negrín, Martín, Laura Díaz, Reyes, Sergio Pitti, González, Ibrahim Hernández, González-Rinne, Federico, González-Delgado, Alejandra, Ferrer-Moure, Carmen, Zulueta, Begoña López-Botet, Torres, Armando, Rodriguez Pérez, Jose Carlos, Gaspari, Flavio, Ortiz, Alberto, Porrini, Esteban
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584992/
https://www.ncbi.nlm.nih.gov/pubmed/35357684
http://dx.doi.org/10.1007/s40620-022-01286-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584992/
https://www.ncbi.nlm.nih.gov/pubmed/35357684
http://dx.doi.org/10.1007/s40620-022-01286-0

Ejemplares similares